SP Industries Acquires Bel-Art Products
SP Industries, Inc. (SP), has acquired privately held Bel-Art Products (Bel-Art). Headquartered in Wayne (NJ, USA), Bel-Art is a global provider of innovative laboratory solutions serving the scientific, industrial and healthcare end markets.
Through this acquisition, SP, which offers a diverse collection of process and laboratory equipment and specialty glassware, adds to its portfolio more than 3500 additional products sold under Bel-Art’s flagship Scienceware and H-B Instrument brand names.
“The acquisition of best-in-class companies that complement our existing product lines and allow us to expand our presence in the global market has proven to be a very effective strategy,” stated SP Industries CEO, Bill Downs. Downs continued by saying, “Bel-Art Products, which will continue operating under its own name, has done a superb job of building brand equity, developing a robust stream of innovative new products, and working with its channel partners to effectively serve the market. We are excited at the increased opportunities to grow market share and will cross-market across brands and leverage each organization’s expertise in product development, operations, finance, and supply chain management.”
Brad Mahood, Chief Operating Officer of Bel-Art, will play a key leadership role in sales, marketing, and product management at the corporate level. In addition, David Landsberger, President of Bel-Art Products, will join the Board of Directors for SP Industries.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance